drugset / Trial / NCT05065177
Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy Infants
RandomizedParallel-groupSingle-blindPrevention
Summary
The purpose of this study is to evaluate the immunogenicity and safety of a live attenuated mumps vaccine in healthy infants between 8 - 18 months old with a commercialized live attenuated mumps vaccine as the control vaccine.
Timeline
- Start
- 2016-01
- Primary completion
- 2016-03
- Completion
- 2016-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Investigational live attenuated mumps vaccine | Vaccine | 0.5 ml | Intramuscular |
| Comparator | control live attenuated mumps vaccine | Vaccine | 0.5 ml | Intramuscular |